Hemangiomas - current therapeutic strategies

Show simple item record

dc.contributor.author Mabeta, Peaceful Lucy
dc.contributor.author Pepper, Michael Sean
dc.date.accessioned 2012-05-29T15:06:00Z
dc.date.available 2012-05-29T15:06:00Z
dc.date.issued 2011-07
dc.description.abstract Hemangiomas are benign neoplasms of the vasculature frequently encountered in children. Several studies have shown that these tumors are characterized by excessive angiogenesis. Although benign, the lesions can present with complications, and may thus require treatment. There are multiple therapeutic options available for patients with problematic or life threatening hemangiomas, some of which have serious side effects. Randomized clinical trials and evidence-based studies on the efficacy of these treatments is still lacking. The recognition that excessive angiogenesis underlies hemangiogenesis offers an opportunity for the development of safer therapeutic strategies that are based on the inhibition of angiogenesis. We review medical therapies currently employed in the management of hemangiomas and the role of angiogenesis inhibition in hemangioma therapy. en_US
dc.description.uri http://www.intjdevbiol.com en_US
dc.identifier.citation Mabeta, P & Pepper, MS 2011, 'Hemangiomas - current therapeutic strategies', International Journal of Developmental Biology, vol. 55, pp. 431-437. en_US
dc.identifier.issn 0214-6282 (print)
dc.identifier.issn 1696-3547 (online)
dc.identifier.other 10.1387/ijdb.103221pm
dc.identifier.other 12791859400
dc.identifier.other G-9725-2014
dc.identifier.uri http://hdl.handle.net/2263/18998
dc.language.iso en en_US
dc.publisher UBC Press en_US
dc.rights © 2011 UBC Press. en_US
dc.subject Hemangioma en_US
dc.subject Anti-angiogenesis en_US
dc.subject Bleomycin en_US
dc.subject Vancristine en_US
dc.subject Propranolol en_US
dc.title Hemangiomas - current therapeutic strategies en_US
dc.type Postprint Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record